Avaleht49BA • FRA
add
BeOne Medicines AG
Viimane sulgemishind
302,00 €
Tänane vahemik
302,00 € - 308,00 €
Aasta vahemik
166,00 € - 322,00 €
Turuväärtus
344,95 mld HKD
Keskmine maht
5,00
P/E suhe
-
Dividendimäär
-
Uudised
Investing.com
13 tunni eest
BeOne Medicines stock price target raised to $408 from $395 at RBC Capital
2,03%
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Käive | 1,41 mld | 41,00% |
Põhitegevusega seonduv kulu | 1,05 mld | 10,64% |
Puhastulu | 124,84 mln | 202,88% |
Puhaskasumimarginaal | 8,84 | 172,94% |
Puhaskasum aktsia kohta | 1,09 | 267,89% |
EBITDA | 198,86 mln | 496,46% |
Tõhus maksumäär | 15,17% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 4,04 mld | 48,74% |
Kogu vara | 7,63 mld | 31,04% |
Kõik kohustused | 3,50 mld | 47,29% |
Kogu omakapital | 4,13 mld | — |
Emiteeritud aktsiate arv | 110,66 mln | — |
Hinna ja väärtuse suhe P/B | 8,09 | — |
Varade tasuvus | 5,85% | — |
Kapitali tasuvus | 8,20% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 124,84 mln | 202,88% |
Põhitegevuse rahakäive | 402,55 mln | 113,70% |
Investeeringute raha | −49,27 mln | 63,20% |
Finantseerimise raha | 961,27 mln | 7 491,79% |
Raha ja raha ekvivalentide muutus | 1,32 mld | 1 286,91% |
Tasuta rahavoog | 306,27 mln | 120,68% |
Teave
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Tegevjuht
Asutatud
28. okt 2010
Veebisait
Töötajate arv
11 000
